NCT03427710View on ClinicalTrials.gov

A First In Human Study to Assess CiVi007 in Subjects With an Elevated LDL-Cholesterol Level

PHASE1CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

February 7, 2018

Primary Completion Date

February 14, 2020

Study Completion Date

August 18, 2020

Conditions
Hypercholesterolemia
Interventions
DRUG

CiVi007

cholesterol lowering drug

OTHER

Placebo

matching placebo to CiVi007

Trial Locations (1)

LS2 9LH

Leeds Clinic, Leeds

Sponsors
All Listed Sponsors
lead

Civi Biopharma, Inc.

INDUSTRY